Sunesis Reports Financial Results for the Third Quarter 2008
Download PDF
- Conference Call Scheduled for Today at 11:00 a.m. EST -

SOUTH SAN FRANCISCO, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ending September 30, 2008.

Total revenue for the third quarter of 2008 was $0.5 million, with a net loss of $7.1 million. As of September 30, 2008, cash, cash equivalents and marketable securities totaled $18.3 million, and debt totaled $1.6 million.

"In the third quarter of this year, we continued to make significant progress moving voreloxin forward in the clinic," said Dan Swisher, Chief Executive Officer of Sunesis. "Enrollment in each of our ongoing ovarian and acute myeloid leukemia (AML) studies is strong, and we look forward to presenting new results from the AML studies at ASH in December."

I cant find any Dec announcement